title: Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation.
abstract: OBJECTIVE
  To assess the safety and efficacy of sustained-release bupropion hydrochloride for adolescent smoking cessation.
  
  
  METHODS
  Prospective, randomized, double-blind, placebo-controlled, dose-ranging trial.
  
  
  METHODS
  Metropolitan areas of Tucson and Phoenix, Arizona.
  
  
  METHODS
  Adolescents (N = 312) recruited through media and various community venues from March 1, 1999, through December 31, 2002, who were aged 14 to 17 years, smoked 6 or more cigarettes per day, had an exhaled carbon monoxide level of 10 ppm or greater, had at least 2 previous quit attempts, and had no other current major psychiatric diagnosis.
  
  
  METHODS
  Sustained-release bupropion hydrochloride, 150 mg/d (n = 105) or 300 mg/d (n = 104), or placebo (n = 103) for 6 weeks, plus weekly brief individual counseling. Subjects were followed up at 12 weeks (by telephone call) and 26 weeks.
  
  
  METHODS
  Confirmed 7-day point prevalence abstinence at 6 weeks and 30-day prolonged abstinence (carbon monoxide level < 10 ppm at each visit; urinary cotinine level < or = 50 microg/L at weeks 2 and 6).
  
  
  RESULTS
  Cotinine-confirmed 7-day point prevalence abstinence rates at 6 weeks were as follows: placebo, 5.6%; 150 mg, 10.7%; and 300 mg, 14.5% (P = .03, 300 mg vs placebo). At 26 weeks, confirmed point prevalence abstinence rates were as follows: placebo, 10.3%; 150 mg, 3.1%; and 300 mg, 13.9% (P = .049). During treatment, confirmed point prevalence rates were significantly higher for 300 mg than placebo at every week except week 4.
  
  
  CONCLUSIONS
  Sustained-release bupropion hydrochloride, 300 mg/d, plus brief counseling demonstrated short-term efficacy for adolescent smoking cessation. Abstinence rates were lower than those reported for adults, with rapid relapse after medication discontinuation.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier: NCT00344695.
authors.affiliation: Department of Family and Community Medicine, The University of Arizona College of Medicine, Tucson, AZ 85704, USA. myram@email.arizona.edu
authors.forename: Myra L
authors.initials: ML
authors.lastname: Muramoto
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Leischow
authors.forename: Duane
authors.initials: D
authors.lastname: Sherrill
authors.forename: Eva
authors.initials: E
authors.lastname: Matthews
authors.forename: Louise J
authors.initials: LJ
authors.lastname: Strayer
mesh_terms: D000293:Adolescent; D016642:Bupropion / Q000008:administration & dosage*; D003376:Counseling; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016540:Smoking Cessation
chemical_list: D003692:Delayed-Action Preparations; D016642:Bupropion